BOTOX, NERVE STIMULATION DEVICES, MIRABEGRON, AND ANTICHOLINERGICS VERSUS BEST SUPPORTIVE CARE FOR OVERACTIVE BLADDER: AN UPDATED US COST-EFFECTIVENESS ANALYSIS

被引：0

作者：

Murray, Brian ^{[1
]}

Miles-Thomas, Jennifer ^{[2
]}

Sussman, David ^{[3
]}

Park, Amy J. ^{[4
]}

Chermansky, Christopher ^{[5
]}

Nguyen, Victor ^{[6
]}

Tung, Amy ^{[7
]}

Gillard, Patrick ^{[7
]}

Lalla, Anjana ^{[7
]}

Nitti, Victor ^{[8
]}

机构：

[1] Capital Reg Urol Surg, Albany, NY USA

[2] Eastern Virginia Med Sch, Virginia Beach, VA USA

[3] Rowan Univ, Sch Osteopath Med, Sewell, NJ USA

[4] Cleveland Clin, Cleveland, OH 44106 USA

[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[6] Curta Consulting Grp, Seattle, WA USA

[7] Allergan, Irvine, CA USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

NEUROUROLOGY AND URODYNAMICS | 2021年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

M73

引用

页码：S157 / S157

页数：1

共 50 条

[21] Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives
Wielage, Ronald C.
Perk, Sinem
Campbell, Noll L.
Klein, Timothy M.
Posta, Linda M.
Yuran, Thomas
Klein, Robert W.
Ng, Daniel B.
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1135 - 1143
[22] Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt
Elsisi, Gihan Hamdy
Nada, Yousery
Rashad, Noha
Carapinha, Joao
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 163 - 168
[23] COST-EFFECTIVENESS COMPARISON OF BOTULINUM TOXIN TYPE A PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITH URINARY INCONTINENCE AMONG PATIENTS NOT ADEQUATELY MANAGED BY ANTICHOLINERGIC THERAPY IN FRANCE
Ruffion, A.
Velard, M.
Loveman, C.
Khalaf, K.
Roze, S.
Pignata, M.
Stanisic, S.
Lister, J.
VALUE IN HEALTH, 2014, 17 (07) : A470 - A470
[24] Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
Ramjee, Lauren
Vurgun, Nesrin
Ngai, Christopher
Patel, Mit
Tremblay, Gabriel
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 213 - 226
[25] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
Maroto, P.
Villavicencio, H.
Pinol, C.
Urruticoechea, L.
VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
[26] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
Gao, X.
Reddy, P.
Dhanda, R.
Gondek, K.
Yeh, Y. C.
Stadler, W. M.
Jonasch, E.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
[27] SACRAL NERVE STIMULATION AND BOTULINUM TOXIN A FOR THE TREATMENT OF REFRACTORY IDIOPATHIC OVERACTIVE BLADDER: AN INDEPENDENT COST-EFFECTIVENESS ANALYSIS IN THE PERSPECTIVE OF ITALIAN NATIONAL HEALTH CARE SERVICE
Bertapelle, M. P.
D'Ausilio, A.
Vottero, M.
Del Popolo, G.
Giannantoni, A.
Mencarini, M.
Ostardo, E.
Spinelli, M.
NEUROUROLOGY AND URODYNAMICS, 2013, 32 (06) : 688 - 688
[28] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US (vol 40, pg 699, 2022)
Goswami, Hardik
Alsumali, Adnan
Jiang, Yiling
Schindler, Matthias
Duke, Elizabeth R.
Cohen, Joshua
Briggs, Andrew
Puenpatom, Amy
PHARMACOECONOMICS, 2023, 41 (05) : 605 - 605
[29] COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN SUCCINATE VERSUS TROSPIUM CHLORIDE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN GERMANY
Hart, W. M.
Nazir, J.
VALUE IN HEALTH, 2012, 15 (04) : A156 - A156
[30] COST-EFFECTIVENESS OF ORAL TOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL-CELL LUNG CANCER (SCLC) IN THE UK
Lykopoulos, K.
Morris, S.
Papo, N.
O'Brien, M. E.
VALUE IN HEALTH, 2008, 11 (06) : A482 - A482

← 1 2 3 4 5 →